Drug Trial Radar · NCT04401982
Measuring the Effects of Netarsudil, Latanoprost, and Combination Therapy on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects
Last checked: Nov 20, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Jul 2, 2026
Primary completion
Mar 17, 2027
Study completion Mar 17, 2027
Sponsor
- Lead sponsor
- University of Maryland, BaltimoreAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Alcon Research
- First posted
- May 26, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to compare participants treated with latanoprost to those treated with Rocklatan (netarsudil/latanoprost) to determine whether the addition of netarsudil results in greater improvements in episcleral venous blood flow in adults with glaucoma or ocular hypertension. Episcleral venous blood flow will be measured using erythrocyte-mediated angiography (EMA) and laser speckle contrast imaging (LSCI). The main questions this study aims to answer are: * Does Rocklatan produce greater increases in episcleral venous blood flow than latanoprost alone? * Can EMA and LSCI reliably detect changes in episcleral venous blood flow following treatment with these medications? Participants will: * Be randomized to receive either latanoprost or Rocklatan * Undergo imaging of the episcleral veins using EMA and LSCI before, during, and after treatment, and * Complete study visits that include standard ophthalmic examinations and intraocular pressure measurements. Hypothesis: The investigators hypothesize that latanoprost, which primarily increases uveoscleral outflow, will not significantly affect the distal episcleral circulation. In contrast, Rocklatan, through its netarsudil component, is expected to produce measurable increases in episcleral venous flow.
Conditions
- Ocular Hypertension
- Suspect Glaucoma
Interventions
Rocklatan (Netarsudil 0.02%/ latanoprost 0.005)Drug
Rocklatan (Netarsudil 0.02%/ latanoprost 0.005) one drop nightly for 14-28 days, if randomized to Rocklatan after 28-35 days on Latanoprost.
Latanoprost (0.005%)Drug
Latanoprost 0.005% one drop nightly for 28-35 days, then 14-28 days if randomized to continue on latanoprost.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Episcleral Venous Blood Flow Measured by Erythrocyte-Mediated Angiography (EMA)Time frame: Baseline (T0), 28-35 days from baseline (T1), 14-28 days from T1 (T2)
- Change in Retinal Arteriolar and Venular Blood Flow Measured by Erythrocyte-Mediated Angiography (EMA)Time frame: Baseline (T0), 28-35 days from baseline (T1), 14-28 days from T1 (T2)
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
University of Maryland Medical Center
Baltimore, Maryland · Recruiting
University Physicians Inc.
Baltimore, Maryland · Recruiting
UM Faculty Physicians, Inc. | 5900 Waterloo Crossing
Columbia, Maryland · Recruiting
Maryland Eye Consultants and Surgeons
Silver Spring, Maryland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.